Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases

Dawiskiba, Tomasz; Deja, Stanisław; Mulak, Agata; Ząbek, Adam; Jawień, Ewa; Pawełka, Dorota; Banasik, Mirosław; Mastalerz-Migas, Agnieszka; Balcerzak, Waldemar; Kaliszewski, Krzysztof; Skóra, Jan; Barć, Piotr; Korta, Krzysztof; Pormańczuk, Kornel; Szyber, P; Litarski, Adam; Młynarz, Piotr

doi:10.3748/wjg.v20.i1.163

Cited by 148 publications

(151 citation statements)

References 56 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…Then, we should clarify whether partial inhibition is clinically relevant effect in animal models. 22) It has been reported that serum amino acid concentration of IBD patients was significantly high when compared to health volunteers, 23,24) which is consistent with the increased expression level of PEPT1 in IBD patients. Furthermore, serum amino acid concentrations were lower in IBD patients in remission status than in IBD active patients.…”

Section: -17)supporting

confidence: 60%

See 1 more Smart Citation

Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn’s Disease on PEPT1

Miyake

Fujishima

Nakai

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

We investigate the inhibitory effect of marketed drugs for treatment of inflammatory bowel disease (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD) on the uptake transporters of peptide transporter 1 (PEPT1), which are up-regulated under the inflamed condition. The uptake transport of glycylsarcosine, a typical substrate for PEPT1, was reduced to 60% only by 5-aminosalicylate at the clinically relevant concentration among tested marketed drugs in PEPT1 transfected HEK293 cell lines. These findings suggest that the inhibition of PEPT1, which were up-regulated in inflamed or non-inflamed site on UC and CD patients, contribute to the clinical effect of commercially available drugs for IBD patients through the inhibition of uptake of antigenic proinflammatory oligopeptides such as formyl-methionine (Met)-leucine (Leu)-phenylalanine (Phe) via PEPT1.

show abstract

Section: -17)supporting

confidence: 60%

“…Furthermore, serum amino acid concentrations were lower in IBD patients in remission status than in IBD active patients. 24) Thus, the inhibition for PEPT1 could be useful to improve the clinical effect by reducing the absorption of causative substances such as bacterial peptide from the intestine.…”

Section: -17)mentioning

confidence: 99%

Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn’s Disease on PEPT1

Miyake

Fujishima

Nakai

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Urinary metabolite profiling allowed to differentiate between UC and CD in only 1 study [40] , whereas 3 other studies failed to do so [41][42][43] . Also for serum metabolomics, discrimination between CD and UC was less pronounced with only 2 studies that were able to separate between patient subtypes.…”

Section: Differentiation Of Ibd Subtypesmentioning

confidence: 99%

“…Besides fecal metabolite profiling, urine profiling can be performed as many microbial metabolites are absorbed from the colonic lumen and excreted in urine, either as such or after further processing by human enzymes. Several studies were able to discriminate IBD patients from HCs based on metabolite profiling of urine samples [40][41][42][43] , but not all [44] . Also, amino acids and amino acid-derived metabolites were found as discriminating compounds in urine.…”

Section: Ibd Disease Signature: Case-control Studiesmentioning

confidence: 99%

“…As compared to urinary and fecal profiles, metabolite profiles in serum or plasma may be less affected by environmental factors and are subject to less inter-individual variation [46] . The metabolite profiling in serum or plasma indicates that both CD and UC have an impact on the lipid metabolism and some products of the amino acid metabolism [42, 43,[47][48][49] .…”

Section: Ibd Disease Signature: Case-control Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics in the Clinical Diagnosis of Inflammatory Bowel Disease

Preter¹

2015

Dig Dis

View full text Add to dashboard Cite

Background: Crohn's disease and ulcerative colitis represent the 2 major phenotypes of inflammatory bowel disease (IBD) that are characterized by chronic inflammation of all or parts of the gastrointestinal tract. The pathogenesis of both diseases is influenced by genetic predispositions as well as microbial and environmental factors. Currently, there is an emerging consensus hypothesis that a microbial dysbiosis is involved in initiating the disease or in maintaining it. These compositional alterations may be reflected in altered metabolic activities of the gut microbiota and has led to the use of ‘omic' profiling to improve the understanding of the pathophysiology of IBD. Key Messages: In the past few years, a metabolic approach has increasingly been applied in a number of studies of experimental and human IBD which were mostly focused on exploring disease-related metabolites to gain more insight into metabolic pathways. Metabolomics involves the high throughput identification, characterization and quantification of small molecule metabolites by different analytical techniques and has been performed in different biofluids such as serum/plasma, urine or fecal samples. The application of such a metabolite profiling technique has revealed different metabolites that allow the discrimination of IBD patients from healthy controls. In addition, separate IBD subtypes could be differentiated. Some of these metabolic changes were directly associated to alterations of specific gut microbial populations, implying a perturbation in the gut microbiome in the development of IBD. Conclusions: This review covers the emerging contribution of metabolomics for the discovery of an IBD signature and to identify biomarkers linked with a metabolic imbalance. For the implementation of metabolomics as a diagnostic tool in IBD, large prospective cohort studies are necessary.

show abstract

Radiation enteropathy‐related depression: A neglectable course of disease by gut bacterial dysbiosis

Liu,

Li,

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

Radiation enteropathy (RE) is common in patients treated with radiotherapy for pelvic–abdominal cancers. Accumulating data indicate that gut commensal bacteria determine intestinal radiosensitivity. Radiotherapy can result in gut bacterial dysbiosis. Gut bacterial dysbiosis contributes to the pathogenesis of RE. Mild to moderate depressive symptoms can be observed in patients with RE in clinical settings; however, the rate of these symptoms has not been reported. Studies have demonstrated that gut bacterial dysbiosis induces depression. In the state of comorbidity, RE and depression may be understood as local and abscopal manifestations of gut bacterial disorders. The ability of comorbid depression to worsen inflammatory bowel disease (IBD) has long been demonstrated and is associated with dysfunction of cholinergic neural anti‐inflammatory pathways. There is a lack of direct evidence for RE comorbid with depression. It is widely accepted that RE shares similar pathophysiologic mechanisms with IBD. Therefore, we may be able to draw on the findings of the relationship between IBD and depression. This review will explore the relationship between gut bacteria, RE, and depression in light of the available evidence and indicate a method for investigating the mechanisms of RE combined with depression. We will also describe new developments in the treatment of RE with probiotics, prebiotics, and fecal microbial transplantation.

show abstract

Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases

Abstract: NMR-based metabolomic fingerprinting of serum and urine has the potential to be a useful tool in distinguishing patients with active IBD from those in remission.

Cited by 148 publications

References 56 publications

Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn’s Disease on PEPT1

Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn’s Disease on PEPT1

Metabolomics in the Clinical Diagnosis of Inflammatory Bowel Disease

Radiation enteropathy‐related depression: A neglectable course of disease by gut bacterial dysbiosis

Contact Info

Product

Resources

About